Cargando…
Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database
BACKGROUND: Studies have found an increased risk of pyoderma gangrenosum associated with rituximab. The structural properties and pharmacological action of rituximab may affect the risk of pyoderma gangrenosum. Additionally, pyoderma gangrenosum is associated with autoimmune disorders for which ritu...
Autores principales: | Hillen, Jodie Belinda, Stanford, Ty, Ward, Michael, Roughead, E. E., Kalisch Ellett, Lisa, Pratt, Nicole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712896/ https://www.ncbi.nlm.nih.gov/pubmed/35933497 http://dx.doi.org/10.1007/s40801-022-00322-6 |
Ejemplares similares
-
Pyoderma gangrenosum controlled with rituximab
por: DaCunha, Matthew, et al.
Publicado: (2019) -
Vulvovaginal pyoderma gangrenosum in association with rituximab
por: Maloney, Catherine, et al.
Publicado: (2018) -
A case of rituximab-induced pyoderma gangrenosum
por: Georgakopoulos, Jorge R., et al.
Publicado: (2018) -
Penile pyoderma gangrenosum
por: Philip, Mariam, et al.
Publicado: (2013) -
Pyoderma gangrenosum: An update
por: Bhat, Ramesh M.
Publicado: (2012)